---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-041584"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2026-04-10T23:59:59+00:00"
generated_at: "2026-05-15T06:40:03.538305+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio prices $10M underwritten offering of common stock and warrants

## Summary
- Pricing of 5,263,156 shares and 5,263,156 warrants at $1.90 per unit, gross proceeds ~$10M.
- Warrants exercisable at $2.50/share, beginning 6 months after issuance, expiring 5.5 years from issue.
- Net proceeds to fund continued clinical development of buntanetap in Phase 3 Alzheimer's study and for working capital.
- Offering expected to close on April 10, 2026; Canaccord Genuity sole bookrunner.

## SEC filing metadata
- accession: 0001104659-26-041584
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2026-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465926041584/0001104659-26-041584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465926041584/tm2611267d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-041584
- JSON: https://secwatch.observer/filing/0001104659-26-041584.json
- Plain text: https://secwatch.observer/filing/0001104659-26-041584.txt

## Source-grounded claims
- claim_id: 4376d0306c992cb76a722970103354732093fb12
  claim: Annovis Bio, Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at Combined offering price of $1.90 per Share and accompanying Warrant, gross proceeds ~$10 million (effective 2026-04-09).
  evidence_excerpt: On April 9, 2026, Annovis Bio, Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of April 9, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in an underwritten registered direct offering (the “Offering”) (i) an aggregate of 5,263,156 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common stock warrants to purchase an aggregate of 5,263,156 shares of Common Stock (the “Warrants” and the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465926041584/0001104659-26-041584-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.